Drugs / T-allo10
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04640987 | Feb 2021 → Mar 2027 expected | hematologic disorder | Porteus, Matthew, MD | Recruiting | No outcome recorded |
| Phase 1 | NCT03198234 | Aug 2017 → Nov 2021 | Hodgkins lymphoma, mixed phenotype acute leukemia, myelodysplastic syndrome, non-Hodgkin lymphoma | Roncarolo, Maria Grazia, MD | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | T-allo10 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03198234 ↗ |
| Modality | Cell therapy | “The cell therapy consists of a cell preparation from the same donor of the HSCT (T-allo10)” NCT03198234 ↗ |
| Route | Intravenous | “T-allo10 cells infused intravenously on Day -1 (day before transplant)” NCT03198234 ↗ |